Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript
Operator: Greetings, and welcome to the Alkermes First Quarter 2026 Financial Results Conference Call. My name is Carrie, and I will be your operator for today's call.
Alkermes Plc. (ALKS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 419,102 | $21,958,848 | +8% | 0.01% |
| 2. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 213,329 | $11,177,372 | -13% | 3.01% |
| 3. | Persistent Asset Partners Xin Huang | 9,338 | $489,265 | -64% | 0.15% |
| 4. | Bailard Inc Thomas Bailard | 4,025 | $210,890 | 0% | |
| 5. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.31 | 35,000 | $815,734.50 | 80,000 | 2022-11-14 | Filing | |
| $23.43 | 427 | $10,004.61 | 9,366 | 2022-03-04 | Filing | |
| $30.22 | 1,650 | $49,860.40 | 1,650 | 2021-08-23 | Filing | |
| $26.43 | 10,000 | $264,269.00 | 10,000 | 2021-08-02 | Filing | |
| $19.65 | 6,940 | $136,371.00 | 11,242 | 2020-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.35 | 44,472 | $2,239,076.26 | 15,395 | 2026-08-03 | Filing | |
| $48.58 | 9,000 | $437,220.00 | 69,389 | 2026-08-03 | Filing | |
| $48.58 | 2,034 | $98,811.72 | 225,456 | 2026-08-03 | Filing | |
| $54.03 | 2,034 | $109,897.02 | 227,490 | 2026-07-06 | Filing | |
| $52.13 | 700 | $36,491.98 | 73,389 | 2026-07-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,235,739 | $1,531,806,565 | 0.02% | |
| 2. | 9,160,575 | $479,968,327 | 0.01% | |
| 3. | 1,097,282 | $57,492,084 | 0.01% | |
| 4. | 983,822 | $51,547,355 | 0.03% | |
| 5. | 916,709 | $48,030,968 | 0.03% |
News See All
10 Stocks Dominating Today's Market Surge: ImmunityBio, Alkermes, and More
On the previous day, SoundHound AI (NASDAQ:SOUN) fell to a 52-week low of $5.83.
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Alkermes plc Fourth Quarter 2025 Financial Results Conference Call. My name is Melissa, and I will be your operator for today's call.
Jim Cramer Recently Looked at These 25 Stocks
We're in critical short supply for all sorts of chips that are needed in the data center... It wasn't easy to forecast this boom, I admit, as recently as one year ago.
Why Analysts are Rating Alkermes (ALKS) a Buy
At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment
Alkermes Plc (NASDAQ:ALKS) is one of the best breakout stocks to invest in.
10 Best Breakout Stocks to Invest In
The US stock market is running high, hitting record highs, bolstered in part by continued optimism around artificial intelligence.
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to Alkermes' Third Quarter 2025 Financial Results Conference Call. My name is Rob, and I'll be your operator for today's call.
HC Wainwright Affirms Alkermes (ALKS) ‘Neutral’ Rating on Vibrance-1 Phase 2 Study
Alkermes (NASDAQ:ALKS) is one of the best beginner stocks to buy, according to analysts. On September 9, HC Wainwright reiterated a ‘Neutral’ rating on the stock and a $46 price target.
Hedge Fund Resource Center